Cdr Life

The startup develops tumor-selective immunotherapies using MHC-specific antibodies that target tumor-specific intracellular antigens. This technology enables healthcare providers to deliver precise treatments to cancer patients, enhancing the effectiveness of immunotherapy.

Aurich

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current cancer immunotherapies often lack tumor selectivity, leading to systemic toxicity and limited efficacy, especially for solid tumors with challenging targets. Existing treatments like engineered cell therapies are complex, individualized, and expensive to manufacture, restricting broad patient access. Autoimmune disease therapies also face challenges in selectively targeting specific immune cell populations without causing widespread immunosuppression.

Solution

CDR-Life is developing next-generation T cell engager (TCE) therapies for cancer and autoimmune diseases, overcoming the limitations of traditional immunotherapies. The company's M-gager® platform generates highly selective antibody-derived TCEs that target both conventional and previously inaccessible tumor antigens, including intracellular antigens presented on MHC, as well as disease-driving immune cell populations. This approach enhances therapeutic efficacy while minimizing off-target effects, potentially expanding the reach of immunotherapies to a wider range of patients. The company's lead program, CDR404, is currently in Phase 1 clinical trials for solid tumors, and the pipeline includes additional candidates targeting various cancers and autoimmune conditions.

Target Audience

The primary target audience includes patients with solid tumors expressing MAGE-A4 and other cancer-specific antigens, as well as individuals suffering from autoimmune diseases requiring targeted immune cell modulation.

Features

M-gager® platform: A proprietary technology for generating highly targeted, antibody-derived T cell engagers
Tumor-selective T cell engagers: Redirect T cell activity towards MAGE-A4 positive tumors and other difficult-to-treat solid tumors
MHC-targeted TCEs: Target intracellular antigens presented on the major histocompatibility complex (MHC)
Dual-target autoimmune therapies: T cell engagers targeting two complementary B cell targets for highly effective B cell depletion
Modular format: Enables selective targeting of diseased cells while sparing healthy tissues
Streamlined manufacturing: Designed with manufacturability in mind, featuring robust stability profiles and established production processes
CDR404: A potent and tumor-selective M-gager® targeting the cancer testis antigen, MAGE-A4, currently in Phase 1 clinical trials